Fixes Record Date for Interim Dividend
Sanofi India Ltd has informed BSE that the Company has fixed August 05, 2016 as the Record Date for the purpose of Payment of Interim Dividend. The said dividend will be paid on August 16, 2016.22-07-2016
22-07-2016
Board declares Interim Dividend
Sanofi India Ltd has informed BSE that the Board of Directors of the Company at its meeting held on July 22, 2016, inter alia, has declared an Interim Dividend of Rs. 18 per Equity share of Rs. 10 each.22-07-2016
Announces Q2 results (Standalone) & Limited Review Report (Standalone) for the Quarter ended June 30, 2016
Sanofi India Ltd has announced the following Unaudited Standalone results for the quarter ended June 30, 2016:The Company has posted a net profit after exceptional items of Rs. 853 million for the quarter ended June 30, 2016 as compared to Rs. 642 million for the quarter ended June 30, 2015. Total Income has increased from Rs. 5596 million for the quarter ended June 30, 2015 to Rs. 6244 million for the quarter ended June 30, 2016.22-07-2016
Sanofi-Synthelabo India launches 2 diabetes drugs
Commenting on the development, Sanofi India Pharmaceutical Operations Country Head & General Manager N Rajaram said: "The launch of two additions to Sanofi India portfolio... The post Sanofi-Synthelabo India launches 2 diabetesdrugs appeared first on The Financial Express.19-07-2016
Old pharma sees new profit cure in cancer drugs
Some of the world's largest drug companies are taking out their checkbooks for acquisitions of smaller peers whose cancer drugs have the potential to cure not just patients, but corporate growth prospects as well.After decades in which progress meant extending life by weeks or months, new cancer treatments hold promise of adding years to patients' lives and billions of dollars in revenue to the companies that own them. Some of the most promising, known as immunotherapy, harness the body's own defense system to fight cancer.For many pharmaceutical companies, this wave of innovation couldn't have come at a better time. A generation of mainstay drugs have gone off patent, raising the stakes for companies vying for a foothold in the burgeoning oncology market.In recent months, executives at many big pharmaceutical companies have expressed interest in building cancer treatment portfolios through acquisitions.They range from well-established incumbents, such as Roche Holding AG and Amgen Inc, to relative outsiders, including Sanofi and Gilead, according to public statements from the companies and several sources familiar with the companies plans and who requested anonymity because they were not authorized to speak to the media.Amgen declined to comment. Roche, Sanofi and Gilead did not respond to requests to comment.Among the most logical acquisition targets are Incyte Corporation and Seattle Genetics, which have respective market capitalizations of about $16 billion and $6 billion, said Michael King, a biotechnology analyst at JMP Securities.Incyte's blood cancer drug, Jakafi, produced more than $600 million in sales last year. Seattle Genetic's lymphoma drug, ADCETRIS, earned revenues of nearly...19-07-2016
Shareholding for the Period Ended June 30, 2016
Sanofi India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click here18-07-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended June 30, 2016
Sanofi India Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended June 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.16-07-2016
Sanofi signs research deal for a Zika vaccine with Pentagon
French drugmaker Sanofi said on Wednesday it had struck a research and development agreement with WRAIR in the US to develop a Zika vaccine candidate.06-07-2016
Q2 results on July 22, 2016
Sanofi India Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on July 22, 2016, for approving the unaudited financial results for the quarter and half year ended June 30, 2016 (Q2).At the said meeting, the Board of Directors will also consider declaration of Interim Dividend for the current financial year ending on December 31, 2016.04-07-2016
Sanofi, BI seek CCI nod for $25-billion global asset swap deal
MUMBAI: European drug giants Sanofi and Boehringer Ingelheim (BI) have filed with the Competition Commission of India for local regulatory clearances that form part of their recently announced global asset swap deal worth $25 billion. The transaction, when completed, will see the $41 billion Sanofi take over Boehringer Ingelheim's consumer healthcare business, excluding China. In exchange, the French drug maker will transfer Merial, its global animal healthcare business, to the family-owned German pharmaceutical group. In their filings to the anti-trust regulator late last week, the two companies submitted that the mutual transfers of neither the consumer healthcare business nor the animal health business will cause an appreciable adverse effect on the competition in any of the potential relevant markets in India. The commission will review if the two companies swapping their businesses will cause any adverse impact on the local competition. Sanofi and Boehringer Ingelheim have been steadily growing their respective businesses in India in the animal health and consumer health products segments. In 2012, Sanofi's animal health business had acquired Mumbai-based Dosch Pharma to bolster its national marketing and distribution presence, helped with 86 products under 50 brands for ruminants, poultry and companion animals. In 2014, as part of its plans to establish and widen its consumer healthcare brands business, Boehringer Ingelheim halted its marketing partnership with Zydus Cadila for two gastrointestinal brands Buscopan and Dulcolax and relaunched those as Buscogast and Dulcoflex via its indigenous marketing division. Swapping of assets is the latest trend witnessed in the global healthcare businesses. In 2014, CCI had...04-07-2016